Company: MDCXW
Filing Date: 2025-09-11
Form Type: DRS
Source: 0001062993-25-015568
Chunk: 6

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-11
Form: DRS
Chunk 6
---
 the Bank of Canada, was $1.00 = C$1.3854.

<div align='center'>ii</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

<div align='center'>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus includes forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this prospectus regarding our strategy, future operations, regulatory process, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "believe", "anticipate", "intend", "expect", "target", "goal", "estimate", "plan", "assume", "may", "will", "predict", "project", "would", "could" and similar expressions or the negative of such terms are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The forward-looking statements in this prospectus include, but are not limited to, statements about:

our financial results, including our ability to continue as a going concern, generate earnings and achieve and sustain profitability, which may vary significantly from forecasts and from period to period;

the progress, timing and completion of our research, development and preclinical studies and clinical trials for our products and product candidates;

our ability to market, commercialize, achieve market acceptance for and sell our products and product candidates;

our ability to develop, manage and maintain our direct sales and marketing organizations;

our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing;

market risks regarding consolidation in the healthcare, pharmaceutical and biotech/life sciences industry;

the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products significantly declines;

our ability to adequately protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;

the fact that product quality issues or product defects may harm our business;

any product liability claims; and

the regulatory, legal and certain operating risks that our operations subject us to.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the